

Zsuzsanna KÃ¼rti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1759290/publications.pdf>

Version: 2024-02-01

26
papers

510
citations

687363

13
h-index

677142

22
g-index

27
all docs

27
docs citations

27
times ranked

1055
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology of inflammatory bowel diseases from west to east. <i>Journal of Digestive Diseases</i> , 2017, 18, 92-98.	1.5	66
2	Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. <i>European Journal of Health Economics</i> , 2014, 15, 121-128.	2.8	41
3	Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease. <i>Quality of Life Research</i> , 2019, 28, 141-152.	3.1	41
4	Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 848-854.	1.5	39
5	Prevalence and predictors of hospitalization in Crohn's disease in a prospective population-based inception cohort from 2000-2012. <i>World Journal of Gastroenterology</i> , 2015, 21, 7272-7280.	3.3	35
6	Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe. <i>World Journal of Gastroenterology</i> , 2015, 21, 6728.	3.3	32
7	Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary: A population-based study based on the National Health Insurance Fund database. <i>Digestive and Liver Disease</i> , 2016, 48, 1302-1307.	0.9	31
8	Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: Results from two referral centres. <i>Digestive and Liver Disease</i> , 2014, 46, 985-990.	0.9	28
9	Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2506-2513.e2.	4.4	24
10	Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases. <i>BMC Gastroenterology</i> , 2017, 17, 97.	2.0	17
11	Low incidence of venous thromboembolism in inflammatory bowel diseases: prevalence and predictors from a population-based inception cohort. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 306-311.	1.5	16
12	Perceived Quality of Care is Associated with Disease Activity, Quality of Life, Work Productivity, and Gender, but not Disease Phenotype: A Prospective Study in a High-volume IBD Centre. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1138-1147.	1.3	15
13	Tuberculin Skin Test and Quantiferon in BCG Vaccinated, Immunosuppressed Patients with Moderate-to-Severe Inflammatory Bowel Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 467-472.	0.9	15
14	Does Hospitalization Predict the Disease Course in Ulcerative Colitis? Prevalence and Predictors of Hospitalization and Re-Hospitalization in Ulcerative Colitis in a Population-based Inception Cohort (2000-2012). <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 287-292.	0.9	14
15	High Adherence to Surveillance Guidelines in Inflammatory Bowel Disease Patients Results in Low Colorectal Cancer and Dysplasia Rates, While Rates of Dysplasia are Low Before the Suggested Onset of Surveillance. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1343-1350.	1.3	13
16	Progress with infliximab biosimilars for inflammatory bowel disease. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 633-640.	3.1	12
17	Harmonization of quality of care in an IBD center impacts disease outcomes: Importance of structure, process indicators and rapid access clinic. <i>Digestive and Liver Disease</i> , 2019, 51, 340-345.	0.9	12
18	Quality of care indicators in inflammatory bowel disease in a tertiary referral center with open access and objective assessment policies. <i>Digestive and Liver Disease</i> , 2018, 50, 37-41.	0.9	9

#	ARTICLE	IF	CITATIONS
19	Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes. <i>World Journal of Gastroenterology</i> , 2020, 26, 759-769.	3.3	8
20	Optimal line of hepatectomy for left lateral living donor liver transplantation according to the anatomical variations of left hepatic duct system. <i>Pediatric Transplantation</i> , 2015, 19, 510-516.	1.0	6
21	“Treat to Target” - Lessons Learnt. <i>Digestive Diseases</i> , 2016, 34, 147-152.	1.9	5
22	The Burden of Anemia Remains Significant over Time in Patients with Inflammatory Bowel Diseases at a Tertiary Referral Center. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 555-559.	0.9	4
23	Therapeutic preferences and outcomes in newly diagnosed patients with Crohn’s diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance Fund database. <i>BMC Gastroenterology</i> , 2018, 18, 23.	2.0	3
24	Optimizing Patient Management in Crohn’s Disease in a Tertiary Referral Center: the Impact of Fast-Track MRI on Patient Management and Outcomes. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2018, 27, 391-397.	0.9	3
25	Can we Predict Disease Course with Clinical Factors?. <i>Current Drug Targets</i> , 2018, 19, 791-797.	2.1	2
26	Adenomatous polyps in ulcerative colitis and colonic Crohn’s disease: less frequent, but does this change surveillance strategy?. <i>Endoscopy</i> , 2016, 48, 210-212.	1.8	1